Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2013)
19 slides from Resonance Health's shareholder meeting presentation, Nov 14, 2013
Slide 1: Annual General Meeting Presentation
ASX: RHT Resonance Health Limited For personal use only Annual General Meeting Presentation 14th November 2013 ASX: RHT AGM 2013
Slide 2: About Resonance Health
About Resonance Health _______________________________________________________________________________________________________ For personal use only Resonance Health Ltd FerriScan® HepaFat-Scan® Fibrosis Other Opportunities • Iron overload • Fatty liver MRI • Liver fibrosis • To increase MRI test te
Slide 3: FerriScan strategy
FerriScan® strategy ________________________________________________________________________________________________ For personal use only • Target clinical trials and drug development for iron Clinical trials overload conditions • Multi-year contracted services Management • 120+ facilities using Fe
Slide 4: FerriScan volume growth
FerriScan® volume growth _________________________________________________________________________________________________ Year on year total volume growth: For personal use only 2012/13 11% growth 2011/12 14% growth 2010/11 14% growth 2009/10 29% growth Total sales volumes by quarter 1400 1200 1000
Slide 5: FerriScan in clinical trials
FerriScan® in clinical trials _________________________________________________________________________________________________ For personal use only Five multi-year contracts signed during the year Approximately 50% of revenue comes from clinical trials using FerriScan® : Project and data managemen
Slide 6: Growing use of FerriScan outside of clinical trials
Growing use of FerriScan® outside of clinical trials For personal use only _________________________________________________________________________________________________ Sales volumes (by quarter) in USA and UK Markets 400 350 300 250 Sales volumes 200 UK 150 USA 100 50 0 AGM 2013
Slide 7: Growth in the use of FerriScan
Growth in the use of FerriScan® _________________________________________________________________________________________________ • 30%+ growth in the UK and US For personal use only • Increase in the number of MRI facilities providing FerriScan® • 30 new FerriScan MRI facilities established in 2012
Slide 8: FerriScan - new FDA approved indication
FerriScan® - new FDA approved indication ______________________________________________________________________________________________ For personal use only FerriScan® received a new FDA approval in January 2013 as a liver iron companion diagnostic device for deferasirox. The FDA stated: “[FerriSca
Slide 9: HepaFat-Scan
HepaFat-Scan® _______________________________________________________________________________________________ For personal use only • FDA submission made for HepaFat-Scan® • Initial submission in mid-2012. The FDA requested changes to the submission path due to the unique characteristics of HepaFat-
Slide 10: HepaFat-Scan market
HepaFat-Scan® market _______________________________________________________________________________________________ For personal use only • Large non-alcoholic fatty liver disease (NAFLD) market • Approximately 30% of the US population has fatty liver disease • NAFLD is the most common cause of liv
Slide 11: Liver fibrosis project
Liver fibrosis project _________________________________________________________________________________________________ • Resonance Health completed a study in 2012 to explore the use of For personal use only MRI to detect and score liver fibrosis in collaboration with Pfizer and the Victorian Live
Slide 12: Summary
Summary _________________________________________________________________________________________________ • Strong growth in FerriScan® sales volumes - mainly in the For personal use only routine clinical use of FerriScan® • Significant increase in number of FerriScan® sites • Strategic partnerships
Slide 13: Financial results
Financial results _________________________________________________________________________________________________ For personal use only Receipts from customers of $1.9m, up 34% from previous year Cash at year end of $1.1m Sales revenue down 2% decline in clinical trial services revenue strong Aust
Slide 14: End of presentation
For personal use only End of presentation AGM 2013
Slide 15: AGM 2013 Resolutions
For personal use only AGM 2013 Resolutions
Slide 16: Proxy Results
Proxy Results For personal use only Resolution 1 Adoption of the Remuneration Report For Against Abstaining Discretionary 27,102,300 883,963 36,700 3,325,521 AGM 2013
Slide 17: Proxy Results
Proxy Results For personal use only Resolution 2 Election of Dr Martin Blake as a Director For Against Abstaining Discretionary 27,912,695 110,268 0 3,325,521 AGM 2013
Slide 18: Proxy Results
Proxy Results For personal use only Resolution 3 Election of Dr Jason Loveridge as a Director For Against Abstaining Discretionary 34,127,190 120,450 0 3,325,521 AGM 2013
Slide 19: Close of meeting
For personal use only Close of meeting AGM 2013
Resonance Health — Shareholder Meeting (November 2013) on 6ix